Workflow
immunoassays
icon
Search documents
BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS
Prnewswire· 2025-05-07 10:30
Core Insights - Bio-Techne Corporation reported strong financial results for the third quarter ending March 31, 2025, with a net sales increase of 4% to $316.2 million and organic revenue growth of 6% compared to the prior year [6][8][23] - The company achieved an adjusted operating margin of 34.9%, up 190 basis points from the previous year, driven by profitability initiatives and volume leverage [4][9][30] - GAAP earnings per share (EPS) decreased to $0.14 from $0.31 in the same quarter last year, while adjusted EPS increased to $0.56 from $0.48 [7][9][28] Financial Performance - Net sales for the third quarter were $316.2 million, a 4% increase year-over-year, with organic revenue growth of 6% [6][8] - GAAP operating income decreased by 42% to $38.7 million, resulting in a GAAP operating margin of 12.2%, down from 22.1% in the prior year [7][30] - Adjusted operating income rose 11% to $110.3 million, with an adjusted operating margin of 34.9% compared to 33.0% in the prior year [9][30] Segment Performance - The Protein Sciences segment reported net sales of $227.7 million, a 6% increase from $214.6 million in the same quarter last year, with an organic revenue growth of 7% [11][30] - The Diagnostics and Spatial Biology segment achieved net sales of $89.2 million, a 2% increase from $87.5 million, with organic revenue growth of 2% [12][30] Non-GAAP Financial Measures - Adjusted EPS for the third quarter was $0.56, an increase from $0.48 in the same quarter last year [9][28] - Adjusted EBITDA for the quarter was $122.2 million, compared to $109.3 million in the prior year [31] - The non-GAAP adjusted tax rate was reported at 21.5%, consistent with the previous year [28][29]
Microbix Presenting at the 2025 Bloom Burton Conference
Globenewswire· 2025-05-01 11:00
Company Overview - Microbix Biosystems Inc. is a life sciences innovator, manufacturer, and exporter, focusing on proprietary biological products for human health [4] - The company has over 120 skilled employees and aims for revenues of C$ 2.0 million or more per month [4] - Microbix specializes in critical ingredients and devices for the global diagnostics industry, including antigens for immunoassays and laboratory quality assessment products (QAPs™) [4][5] Product and Service Offerings - Microbix's antigens support antibody tests for approximately 100 diagnostics makers, while QAPs are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs [4] - The company also develops proprietary products such as Kinlytic, a biologic thrombolytic drug for treating blood clots, and reagents for molecular diagnostic testing [5] Conference Participation - Microbix will attend and present at the 2025 Bloom Burton & Co. Healthcare Investor Conference on May 5 & 6, 2025 [1][2] - CEO Cameron Groome will present to investors on May 6 at 2:30 p.m. Eastern Time, and senior management will engage in one-on-one meetings with investors [2] Industry Context - The Bloom Burton & Co. Conference aims to connect investors with developments in the Canadian healthcare and life sciences sector [2][3] - Bloom Burton & Co. provides capital raising, M&A advisory, equity research, and strategic advisory services to accelerate returns in the healthcare sector [3]